Abiopharma

🔍 Sanofi (Executive)

Company: Latigo Biotherapeutics, Inc. (LTGO)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 494,800 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: C | equity_swap_involved: false | shares_owned_after: 494,800.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Acquired 177,978 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: C | equity_swap_involved: false | shares_owned_after: 672,788.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
• Sold 494,800 shares of Series B Preferred Stock (Derivative)
  Date: 2026-08-10 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F3, F3
• Sold 177,978 shares of Convertible Promissory Note (Derivative)
  Date: 2026-08-10 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2, F3, F3

Footnotes:

• F1: The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration.
• F2: The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock.
• F3: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
• REMARKS: Immediately upon consummation of the IPO, Sanofi's beneficial ownership of the common stock fell below 10%, as a result of the issuance of additional shares of common stock. The convertibility and expiration of the Preferred Stock and Note prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 12, 2026.